Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Hepatology. 2025 Aug 1;82(2):E40.
doi: 10.1097/HEP.0000000000001401.
Epub 2025 Jun 25.